The survival rate for people with advanced bladder cancer is less than a year, making it the fourth most common cancer diagnosed in men. The bladder cancer patients who will benefit from immunotherapy are unknown to doctors.
According to clinical trial results, immunotherapy after surgery increased bladder cancer patients' chance of staying cancer-free compared to patients who received a placebo.
London [UK], September 18 (ANI): An immunotherapy drug called 'avelumab' has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial.
Washington D.C. [USA], April 12 (ANI): Treating metastatic bladder cancer patients with immunotherapy immediately after their chemotherapy significantly slows down the progression of cancer, suggests a study based on a clinical trial.